News & Events about Passage Bio Inc.
Passage Bio, Inc. (NASDAQ:PASG Free Report) major shareholder Orbimed Advisors Llc bought 617,382 shares of the companys stock in a transaction dated Tuesday, June 27th. The stock was purchased at an average price of $0.84 per share, with a total value of $518,600.88. Following the ...
PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET...
Additional interim biomarker and efficacy data from first six patients continue to demonstrate both the high and low dose of PBGM01 led to a biological effect in patientsPBGM01 administration resulted in stabilization of MRI severity scores in all treated patients through 6 to twelve months of ...
PHILADELPHIA, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced the appointment of William Chou, M.D. as chief executive officer (...